Bayer Devoting $350 Mil. For OTC Line Extensions, New Indications
This article was originally published in The Tan Sheet
Executive Summary
Bayer Worldwide Consumer Care plans to invest $350 mil. on R&D over the next five years, Consumer Care Division President Gary Balkema reported in a March 30 teleconference discussing the company's 1998 results. The company will focus on cultivating line extensions and new indications for existing products.
You may also be interested in...
Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication
Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients
Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication
Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients
Bayer Aleve sNDA Approval Provides Midol Brand 12-Hour Relief Indication
Bayer's Midol menstrual pain franchise soon could include SKUs with three different primary OTC pain relief ingredients